Score Overview
See the full market ranking โ
Denali Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 335M to $ 0.00 and net income went from $ 71M to -$ 512M. Revenue increased in 2 of those 5 years; net income in 2.
Denali Therapeutics Inc currently holds a 5-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 25.27 | โ |
1 Year2025-08-12 | $ 13.22 | 91.15% |
5 Years2021-08-12 | $ 52.93 | -52.26% |
All Time2017-12-08 | $ 21.45 | 17.81% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2017-12-08 |
|---|---|---|---|---|
| Price | $ 25.27 | $ 13.22 | $ 52.93 | $ 21.45 |
| Return | โ | 91.15% | -52.26% | 17.81% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 508M | $ 987M |
| 2025 | $ 0.00 | -$ 512M | $ 867M |
| 2024 | $ 0.00 | -$ 422M | $ 832M |
| 2023 | $ 330M | -$ 145M | $ 1.03B |
| 2022 | $ 108M | -$ 325M | $ 1.33B |
| 2021 | $ 48M | -$ 290M | $ 865M |
| 2020 | $ 335M | $ 71M | $ 1.46B |
| 2019 | $ 26M | -$ 197M | $ 415M |
| 2018 | $ 129M | -$ 36M | $ 464M |
| IPO2017 | $ 0.00 | -$ 88M | $ 406M |
Explore beyond DNLI
You're looking at Denali Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score โ 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.